Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis

Q: What is the SNDX stock price target?

Take-profit $34.15 (+76.6% upside). Prior stop was $18.43.

Q: What are the risks of investing in SNDX?

Concentration risk — Product: Revuforj and Niktimvo; Concentration risk — Counterparty: Incyte; Quality below floor (2.5 < 4.0); Quality below floor (2.5 < 4.0); Momentum score 2.7/10 — below 4.5 minimum.

Q: Is SNDX overvalued or undervalued?

Syndax Pharmaceuticals, Inc. trades at a P/E of N/A (forward -93.6). TrendMatrix value score: 7.4/10. Overall verdict: Sell.

Q: What do analysts say about SNDX?

20 analysts cover SNDX with a consensus score of 4.3/5. Average price target: $39.

Q: What does Syndax Pharmaceuticals, Inc. do?

Syndax Pharmaceuticals is a commercial-stage biopharma with two FDA-approved oncology products: Revuforj (revumenib, launched Nov 2024) for R/R acute leukemia with KMT2A translocation or NPM1 mutation, and Niktimvo (axatilimab-csfr, launched Jan 2025) for cGVHD after two prior lines of therapy, the latter co-commercialized with Incyte. The company has never previously marketed a product and generates revenue primarily from Revuforj and Niktimvo sales.

SellModerate ConfidenceUpdated 1 days ago (May 19, 2026, 2:36 PM ET)

Healthcare · Biotechnology

$19.34+76.6% A.UpsideScore 4.9/10#102 of 157 Biotechnology

QualityF-score3 / 9FCF yield-10.81%

Stop $18.43Target $34.15(analyst − 13%)A.R:R 6.5:1

Analyst target$39.25+102.9%12 analysts

$34.15our TP

$19.34price

$39.25mean

$57

Sell if holding. Engine safety override at $19.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 11.92; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Syndax Pharmaceuticals, Inc.

Latest news

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $37 — benzinga May 13, 2026 neutral
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $37 — benzinga May 1, 2026 positive
Syndax Pharmaceuticals Q1 EPS $(0.48) Beats $(0.64) Estimate, Sales $64.864M Miss $70.439M Estimate — benzinga Apr 30, 2026 negative
Earnings Scheduled For April 30, 2026 — benzinga Apr 30, 2026 neutral

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Product: Revuforj and Niktimvo

Concentration risk — Counterparty: Incyte

Quality below floor (2.5 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-93.6

Mkt Cap$1.7B

EV/EBITDA-7.6

Profit Mgn-112.0%

ROE-189.5%

Rev Growth223.6%

Beta0.41

DividendNone

Rating analysts20

Quality Signals

Piotroski F3/9

Options Flow

P/C11.92bearish

IV76%elevated

Max Pain$15-22.4% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductRevuforj and Niktimvo
10-K Item 1A: 'Our business depends heavily on our ability to successfully commercialize Revuforj and Niktimvo in the United States'
HIGHcounterpartyIncyte
10-K Item 1A: 'We are dependent upon our collaboration with Incyte to further develop and commercialize axatilimab.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.415%1.11

Quality2.515%0.38

Growth5.015%0.75

Momentum2.710%0.27

Sentiment8.110%0.81

Insider Activity5.010%0.50

Peer Rank3.810%0.38

Technical Setup7.95%0.40

Risk Profile1.95%0.10

Catalyst4.95%0.25

Overall (Σ contributions)4.93

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Put Call

0.0

Debt Equity

0.0

Implied Vol

0.6

Short Interest

1.2

Max Pain Risk

3.0

Beta

10.0

High short interest justified: 23%Elevated put/call: 11.92High IV: 76%Above max pain $15Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roa

0.0

Operating Margin

0.0

Fcf Quality

0.0

Piotroski F

3.3

Moat

4.2

Current Ratio

7.5

Cash-burning: FCF -86% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume

0.0

Obv

1.0

Macd

2.8

Ma Position

4.0

Rsi

5.5

Volume distribution (falling OBV)Above 200-day MA

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Value Rank

5.6

Growth Rank

9.5

Industry growth leader

GatesMomentum 2.7<4.5A.R:R 6.5 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 76d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

43 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.00Resistance $23.70

Price Targets

$18

$34

A.Upside+76.6%

A.R:R6.5:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.5 < 4.0)

! Momentum score 2.7/10 — below 4.5 minimum

Earnings

3/4 beats

Next Earnings2026-08-03 (76d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is SNDX stock a buy right now?

Sell if holding. Engine safety override at $19.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 11.92; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $18.43. Score 4.9/10, moderate confidence.

What is the SNDX stock price target?

Take-profit target: $34.15 (+76.6% upside). Prior stop was $18.43. Stop-loss: $18.43.

What are the risks of investing in SNDX?

Concentration risk — Product: Revuforj and Niktimvo; Concentration risk — Counterparty: Incyte; Quality below floor (2.5 < 4.0).

Is SNDX overvalued or undervalued?

Syndax Pharmaceuticals, Inc. trades at a P/E of N/A (forward -93.6). TrendMatrix value score: 7.4/10. Verdict: Sell.

What do analysts say about SNDX?

20 analysts cover SNDX with a consensus score of 4.3/5. Average price target: $39.

What does Syndax Pharmaceuticals, Inc. do?Syndax Pharmaceuticals is a commercial-stage biopharma with two FDA-approved oncology products: Revuforj (revumenib,...

Syndax Pharmaceuticals is a commercial-stage biopharma with two FDA-approved oncology products: Revuforj (revumenib, launched Nov 2024) for R/R acute leukemia with KMT2A translocation or NPM1 mutation, and Niktimvo (axatilimab-csfr, launched Jan 2025) for cGVHD after two prior lines of therapy, the latter co-commercialized with Incyte. The company has never previously marketed a product and generates revenue primarily from Revuforj and Niktimvo sales.